(Q37187383)

18 August 2017

1 reference

title

Mechanisms of disease: temozolomide and glioblastoma--look to the future (English)

1 reference

18 August 2017

0 references

Maciej M Mrugala

1

1 reference

18 August 2017

Marc C Chamberlain

series ordinal

2

1 reference

18 August 2017

publication date

10 June 2008

1 reference

Nature Clinical Practice Oncology

18 August 2017

published in

1 reference

18 August 2017

volume

5

1 reference

18 August 2017

issue

8

1 reference

18 August 2017

page(s)

476-486

1 reference

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Pharmacological rescue of mutant p53 conformation and function

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Survival of human glioma cells treated with various combination of temozolomide and X-rays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Targeted modulation of MGMT: clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

ZD6474--clinical experience to date

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Integrins: a family of cell surface receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Synergistic antiglioma activity of radiotherapy and enzastaurin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1155

7 January 2021

Identifiers

DOI

10.1038/NCPONC1155

1 reference

release_ik2obd6do5cfxjty4mcyjrm6ee

18 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ik2obd6do5cfxjty4mcyjrm6ee

24 November 2022

mapped directly with Wikidata item

1 reference